ES2178633T3 - Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos. - Google Patents

Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos.

Info

Publication number
ES2178633T3
ES2178633T3 ES91910904T ES91910904T ES2178633T3 ES 2178633 T3 ES2178633 T3 ES 2178633T3 ES 91910904 T ES91910904 T ES 91910904T ES 91910904 T ES91910904 T ES 91910904T ES 2178633 T3 ES2178633 T3 ES 2178633T3
Authority
ES
Spain
Prior art keywords
growth factor
beta
insulin
concomitating
fci
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91910904T
Other languages
English (en)
Inventor
Harry N Antoniodes
Samuel E Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Institute of Molecular Biology Inc
Original Assignee
Harvard College
Institute of Molecular Biology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Institute of Molecular Biology Inc filed Critical Harvard College
Application granted granted Critical
Publication of ES2178633T3 publication Critical patent/ES2178633T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA CURACION DE UNA HERIDA EXTERNA Y/O REGENERACION OSEA DE UN MAMIFERO ADMINISTRANDOLE UNA COMPOSICION QUE CONTIENE FACTOR BETA DEL CRECIMIENTO PURIFICADO DE TRANSFORMACION Y FACTOR-I DEL CRECIMIENTO PURIFICADO PARECIDO A LA INSULINA O FACTOR-II DEL CRECIMIENTO PURIFICADO PARECIDO A LA INSULINA.
ES91910904T 1990-05-30 1991-05-30 Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos. Expired - Lifetime ES2178633T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53064990A 1990-05-30 1990-05-30

Publications (1)

Publication Number Publication Date
ES2178633T3 true ES2178633T3 (es) 2003-01-01

Family

ID=24114431

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91910904T Expired - Lifetime ES2178633T3 (es) 1990-05-30 1991-05-30 Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos.

Country Status (7)

Country Link
EP (1) EP0531425B1 (es)
JP (1) JP3377524B2 (es)
AT (1) ATE222117T1 (es)
CA (1) CA2082420C (es)
DE (1) DE69133087T2 (es)
ES (1) ES2178633T3 (es)
WO (1) WO1991018622A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288628A (en) * 1992-06-24 1994-02-22 The Procter & Gamble Company Rat osteosarcoma cell line OSR4TR1
US5292656A (en) * 1992-06-24 1994-03-08 The Procter & Gamble Company Rat osteosarcoma cell line OSR-6
US5286645A (en) * 1992-06-24 1994-02-15 The Procter & Gamble Company Rat osteosarcoma cell line osr3tr1
US5286643A (en) * 1992-06-24 1994-02-15 The Procter & Gamble Company Rat osteosarcoma cell line OSR-8
US5286644A (en) * 1992-06-24 1994-02-15 The Procter & Gamble Company Rat osteosarcoma cell line OSR-2
US5264358A (en) * 1992-06-24 1993-11-23 The Procter & Gamble Company Rat osteosarcoma cell line OSR9TR1
KR100385293B1 (ko) * 2000-05-13 2003-05-23 주식회사 리젠 바이오텍 βｉｇ-ｈ3의 일부 도메인을 이용한 세포 부착 및 창상치유 방법
GB2369572A (en) 2000-11-29 2002-06-05 Raft Trustees Ltd Wound treatment composition comprising insulin
JP2014156410A (ja) * 2013-02-14 2014-08-28 Nagoya Univ 組織形成用組成物及びその利用
MX2017004520A (es) 2014-10-14 2018-03-15 Lynch Samuel Composiciones para tratar heridas.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS61291521A (ja) * 1983-06-03 1986-12-22 アメリカ合衆国 ヒト血小板もしくはヒト胎盤由来の精製β型トランスホ−ミング成長因子
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
ATE84065T1 (de) * 1986-10-09 1993-01-15 Fujisawa Pharmaceutical Co Expressionsvektor fuer menschlichen insulinaehnlichen wachstumsfaktor-i.
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
KR960005708B1 (ko) * 1986-11-14 1996-05-01 인스티튜트 오브 몰레큘러 바이올로지, 인코오포레이티드 외상 치료 및 뼈 재생용 조성물
AU1340688A (en) * 1987-01-30 1988-08-24 Techne Corporation Transforming growth factor-beta
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
EP0323842A3 (en) * 1988-01-07 1990-04-25 Otsuka Pharmaceutical Co., Ltd. Method of purification of transforming growth factor-beta
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
EP0424416B1 (en) * 1988-07-15 1995-07-19 Central Sydney Area Health Service Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
NZ236618A (en) * 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound

Also Published As

Publication number Publication date
CA2082420A1 (en) 1991-12-01
CA2082420C (en) 2004-07-20
EP0531425A1 (en) 1993-03-17
DE69133087D1 (de) 2002-09-19
DE69133087T2 (de) 2003-04-03
EP0531425A4 (en) 1997-08-27
JPH05507488A (ja) 1993-10-28
JP3377524B2 (ja) 2003-02-17
WO1991018622A1 (en) 1991-12-12
EP0531425B1 (en) 2002-08-14
ATE222117T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
OA09159A (en) Wound healing and bone regeneration.
DE68917300T2 (de) Heilung von wunden.
RU94046291A (ru) Способ профилактики и лечения периферической невропатии, композиция, содержащая инсулин-подобный фактор роста i
MX165863B (es) Barrera que evita la adhesion, que contiene heparina y procedimiento para prepararla
ATE198835T1 (de) Knochenwachstumsfördernde zusammensetzung
ES2178633T3 (es) Utilizacion concomitante del factor -i de crecimiento similar a insulina (en lo sucesivo "fci-i") y el factor de crecimiento transformante beta (en la sucesivo "fct-beta") para la fabricacion de un medicamento para la regeneracion de huesos en mamiferos.
DE69116184T2 (de) Topisch anwendbare Zusammensetzungen auf der Basis von hoch molekularer Hyaluronsäure zur Behandlung von Entzündungen der Mundhöhle, zu deren Hygiene und kosmetischer Behandlung
ES2081968T3 (es) Equipo para la purificacion de sangre.
ES2062292T3 (es) Un proceso para la preparacion del compuesto que tiene la estructura (7alfa,17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-in-3-ona.
DE69031218D1 (de) Wundheilung
MX9301387A (es) Metodo y composicion para el tratamiento de osteoporosis.
ES2174838T3 (es) Metodo para aumentar la absorcion del intestino.
ES2132082T3 (es) Composiciones para cicatrizar heridas que contienen el factor de crecimiento fibroplasto y acido ascorbico.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ZA905422B (en) Substituted 2-imidazolines and preparation and use thereof
ATE105563T1 (de) Retinsaeureester von l-cladinos, verfahren zu deren herstellung und ihre verwendung in der human- oder veterinaermedizin und in der kosmetik.
DE69008761D1 (de) Retinsäureester von D-Desosamin, Verfahren zu deren Herstellung und ihre Verwendung in der Human- oder Veterinärmedizin und in der Kosmetik.
ATE6639T1 (de) Ein gereinigtes polypeptid, ein verfahren zu dessen herstellung, dessen anwendung und das enthaltende pharmazeutische praeparat.
DK0741746T3 (da) Thymosin alpha 1-analoger